Compare FSUN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | EVO |
|---|---|---|
| Founded | 1892 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 966.0M | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | FSUN | EVO |
|---|---|---|
| Price | $38.93 | $3.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $46.33 | $7.00 |
| AVG Volume (30 Days) | 100.0K | ★ 213.1K |
| Earning Date | 01-26-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.52 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | $384,497,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $62.50 | $8.52 |
| P/E Ratio | $12.27 | ★ N/A |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $29.95 | $2.84 |
| 52 Week High | $45.32 | $4.80 |
| Indicator | FSUN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.37 | 60.22 |
| Support Level | $37.73 | $3.58 |
| Resistance Level | $39.57 | $3.87 |
| Average True Range (ATR) | 0.92 | 0.08 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 56.99 | 67.09 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments - Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.